SL Science: A $1.15 Billion Valuation Built On Preclinical Promises
Click to view quick news summary (Spoiler)
SL Science's $1.15 billion valuation relies entirely on its preclinical Gamma Delta T (GDT) cell therapy pipeline, prompting analysts to rate the stock as a Sell due to significant risks.
SL Science Holding Limited (SLBT) is a biotechnology company based in Taiwan that operates on two totally different fronts. In June 2026, the company went public through a reverse merger with a special purpose acquisition company (SPAC) called Horizon Space Acquisition II Corp. At first, this transaction gave the entity an equity value of over $5.5 billion, but since then, the stock has experienced massive volatility, crashing from $14.50 down to roughly $2.06 per share. However, despite this huge selloff, the company still has a market cap of roughly $1.15 billion.
Despite their already huge fall, I still rate the company as a Sell, because their whole valuation relies entirely on a cellular therapy pipeline that is completely preclinical. The fair risk-adjusted value of the company is still much lower than the current trading price, meaning that the $1.15 billion valuation is still heavily overblown and leaves no safety margin. In this article I will introduce the company, present the risks and rewards, and calculate the fair value, based on which I will explain my bearish stance.
Main Pipeline Drug
The flagship investigational platform of SL Science relies on Gamma Delta T (GDT) cell therapy. This therapy is currently being developed to target aggressive solid tumors like glioblastoma (brain cancer) and pancreatic cancer. The reason why the therapy could have some potential (compared to the competition) is mainly because of its allogeneic and scalable design. Standard autologous T-cell therapies often struggle or fail to penetrate the immunosuppressive microenvironment of solid tumors, but SL Science believes that their licensed GDT platform can overcome these barriers and successfully treat them.
The way the therapy works is that it utilizes exosomes derived from the GDT cells, which preclinical models have shown can cross the blood-brain barrier and lead to the death of cancer cells. But trials have not yet been conducted on a single human, meaning that the probability of success is extremely low and the stock price is extremely volatile. A slight positive, though, is that in August 2026, the licensor filed a U.S. FDA Drug Master File (DMF No. 044612) covering these GDT-derived exosomes, adding to an existing DMF for the GDT cells themselves. Furthermore, in March 2026, management submitted an Orphan Drug Designation request to the FDA, which was formally acknowledged for review in July 2026. Despite these efforts, neither the DMF nor the Orphan Drug Designation request directly increases the chances of approval or guarantees clinical success.
The market for solid tumors like glioblastoma is rather large. In the US alone, there are roughly 12,000 to 13,000 new cases of glioblastoma diagnosed each year. Because this specific cancer is very aggressive, with very few treatment options, advanced cell therapies in this space generally cost on average anywhere from $400,000 to $500,000 per patient. If SL Science’s GDT therapy eventually manages to reach the market and captures just 1,000 to 1,250 patients annually (roughly 8% to 10% of the total US market), at a conservative cost of $400,000 per treatment, the drug could theoretically generate around $500 million in peak annual revenue.
However, as SL Science’s entire therapeutic pipeline is fully preclinical, it will likely take at least 10 years to complete the full three-phase clinical cycle (if a future designation grant does not allow for a faster testing cycle). This means the company will have to burn enormous amounts of cash to get the pipeline through testing, and considering that they currently do not have any partners and very little cash in the bank, heavy shareholder dilution in the future is almost inevitable, while the probability of success is rather low.
Other Pipeline Drugs
Even though SL Science’s valuation is currently mainly relying on its GDT cell therapy, solid tumors are not the only market they are targeting. The company is also working on a secondary preclinical platform utilizing CD-19 Armed-T cells, aimed at various oncology indications. But more interestingly, they actually operate an already fully commercialized cosmetic and skincare segment, which does generate the company revenue, although not a substantial amount.
For the fiscal year ending December 31, 2025, SL Science reported a net revenue of just $2.20 million from this cosmetic segment, which was actually a 35% decrease YOY. While the segment does generate cash, it is certainly not enough to fund the future testing of the currently preclinical oncology pipeline.
